Keratoconjunctivitis Sicca — Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
Citation(s)
A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Keratoconjunctivitis Sicca